On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Esophageal Cancer.

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Hepatocellular Carcinoma.

Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...

rohit sharma ki wife Everest Medicines' Phase 3 Clinical Trial Application for Sacituzumab Govitecan Approved Pharmaceutical and Health Industry Weekly Report (September 23-September 27) [Two Sessions ...

INR:5297. bet365 founded The latest clinical progress of CRISPR/Cas9 gene editing therapy Everest Medicines' Phase 3 Clinical Trial Application for Sacituzumab Gov ...

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

Sacituzumab govitecan failed to improve overall survival in the EVOKE-01 trial, but was well tolerated with no new safety signals. Comprehensive genomic profiling is crucial to address testing ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...

Gilead Sciences announced that the FDA has granted Breakthrough Therapy Designation to breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive ...